Global Prostrate Cancer Diagnostics Market By Type (Screening Tests (Digital rectal exam (DRE), Prostate-specific antigen (PSA) test), Confirmatory Tests (PCA3Test, Transrectal Ultrasound, Prostate Biopsy, MRI Fusion), Blood-based assay, Others); By Cancer Types (Acinar Adenocarcinoma, Ductal Adenocarcinoma, Transitional Cell (Or Urothelial) Cancer, Squamous Cell Cancer, Small Cell Prostate Cancer); By Region (U.S., Canada, Mexico, Rest of North America, The UK, France, Germany, Italy, Spain, Nordic Countries (Denmark, Finland, Iceland, Sweden, Norway),Benelux Union (Belgium, the Netherlands, Luxembourg), Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia (Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia), Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa, Brazil, Argentina, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2019 - 2027
Industry Trends
Prostate cancer is a form of cancer that affects the prostate gland, which is a small gland in the pelvis of men located next to the bladder. It is caused due to abnormal growth of cells in the prostate and is highly influenced by an individual's age, race, family history, obesity, amongst others factors. If not diagnosed and treated early, prostate cancer can lead to severe health conditions. The cancer can spread to bones, rectum, and other body parts. Furthermore, severe discomforts in the pelvic area, coupled with urinary issues can be experienced by the individual as the cancer spreads. The World Cancer Research Fund International states that prostate cancer is the second most commonly occurring cancer in men, and the fourth most commonly occurring cancer overall. There were around 1.3 million new cases in 2018. There is a rise in the number of individuals that are being affected by prostate cancer. However, early detection of prostate cancer ensures in higher success rate in terms of treatment and reduces fatalities .The detection of prostate cancer when it is still confined to the prostate gland is of utmost importance for effective treatment. The growing awareness of the importance of early detection of prostate cancer is increasing demand for diagnostics amongst individuals. The diagnostics of prostate cancer includes a wide array of digital and biological tests for screening and confirming the presence of malignant tumour as well as the cancer stage. Companies such as OPKO Health, Inc. and Abbott are providing testing equipment for prostate cancer. Thus, the prevalence of prostate cancer and the growing demand for early detection and treatment, especially among men above the age of 55, is driving the growth of the prostate cancer diagnostics market.
The higher testing time of prostate cancer diagnostic equipments, and the higher costs associated with prostate cancer testing is a cause of concern amongst individuals. This is hampering the growth of the global prostate cancer diagnostics market. Medical professionals use biopsies, immunoassays and other techniques for rectal examination of patients. These procedures are time consuming, and cost a hefty amount, especially in private healthcare facilities. To overcome these challenges, researchers are developing novel techniques based on nuclear medicine and radiopharmaceuticals which helps in reducing costs and the waiting period. Thus, the advancement in testing technology helps in providing cost-effective solutions to the individuals and is expected to overcome the hindrances in the global prostate cancer diagnostics market during the forecast years.
The market participants are incorporating technologies such as artificial intelligence (AI) in their offerings to increase the accuracy of diagnosis and bring down testing costs. Artificial intelligence algorithms have the potential to accurately detect and grade prostate cancer in biopsy samples with proper training. Ibex Medical Analytics Ltd., for instance, is an Israeli start-up that has deployed AI-based solution for prostate cancer detection at CorePlusServiciosClínicos y Patológicos, LLC facility in September 2020. Similarly, Anixa Biosciences, Inc. launched an AI driven platform called Cchek in December 2019 for flow cytometry-based liquid biopsy that aids in faster detection of prostate cancer in men. Also, numerous government bodies are increasingly focussing on the development of new technologies to raise the efficiency of prostate cancer diagnostics. Swedish Research Council, for instance, funded a study in January 2020 for the development of an AI system for effectively handling the increasing volume of prostate cancer biopsies, which helps in mass diagnostics. Thus, the integration of advanced technologies such as AI with traditional diagnosis techniques is anticipated to pose lucrative growth opportunities for the market participants in the global prostate cancer diagnostics market during the coming years.
Patients with prostate cancer are vulnerable to COVID-19 infection. The chances of prostate cancer patients getting affected by the coronavirus are considerably reduced with the application of androgen-deprivation therapies. The vulnerability of prostate cancer patients of getting affected by COVID-19 is increasing the demand for prostate cancer diagnostics. Also, as the lockdown measures imposed by several countries like India, the UK, France, etc., to contain the spread of COVID-19 pandemic are being eased, medical professionals are expanding their diagnostics capabilities to cater to the those individuals who had to delay the tests during the lockdown months. For instance, Prostate Conditions Education Council (PCEC) of Colorado announced that they will be expanding their prostate cancer testing capability to cater to more than 23,000 men who had to delay their treatment due to COVID-19. Thus, the COVID-19 pandemic is anticipated to have a positive impact on the global prostate cancer diagnostics market.
Type Outlook:
Prostate cancer is mostly detected during the initial screening tests. However, these tests might fail to detect cancerous cells in some patients, thereby reducing its reliability. The American Cancer Society, Inc. stated that screening tests alone are not enough to diagnose prostate cancer in an individual. This is creating a higher demand for confirmatory tests. Prostate biopsy is a highly popular confirmatory test which is used in prostate cancer diagnostics. In this method, the digital imaging of the prostate is performed, which is followed by a sample collection through insertion of a hollow needle. When the needle is pulled out, it removes small cylindrical tissue samples. The process is repeated several times to get an accurate result. The use of spring loaded biopsy instrument or a numbing agent reduces the pain associated with this process. These samples are then examined under a microscope to evaluate the presence of cancerous cells. Researchers are further developing more efficient and safer technologies for obtaining prostate biopsies. For instance, the University of Cambridge have begun clinical trials of a new prostate biopsy device in February 2019. The device reduces the risk of urinary infections or sepsis during the aforementioned procedure. Thus, the higher reliability offered by the confirmatory tests are propelling the revenue share of these tests in the global prostate cancer diagnostics market.
Regional Outlook:
North America region accounted for the highest share in the global prostate cancer diagnostics market in 2018. This can be attributed to the high prevalence of prostate cancer in the geriatric and overweight populace. The National Cancer Institute, an agency under the U.S Department of Health and Human Services, stated that around 174,650 new cases were diagnosed across the country in 2019. The growing number of prostate cancer patients in the region is creating high demand for diagnostics devices. Government agencies have recognized the rise in demand and have initiated a number of programs for prostate cancer diagnostics. Approval for new products are also under way. For instance, FoundationOne Liquid CDx from Foundation Medicine Inc., and BRACAnalysisCDx from Myriad Genetics, Inc, are some of the products that have received clearance from the U.S Food and Drug Administration agency in recent years. Thus, the growing number of prostate cancer patients in the region, coupled with the emergence of new market players with novel offerings, is aiding in the growth of the North American prostate cancer diagnostics market.
In terms of revenue, global prostate cancer diagnostics market was valued at US$ 732.64 Mn in 2018 and is anticipated to grow at a CAGR of 9.59% over the forecast period. The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Prostate Cancer Diagnostics Market Revenue & Forecast, (US$ Million), 2015 – 2027
Competitive Landscape
The report provides both, qualitative and quantitative research of prostate cancer diagnostics market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the prostate cancer diagnostics market are Exosome Diagnostics, Genomic Health, Inc., MDxHealth, MINOMIC, Roche Diagnostics and Siemens Healthcare Private Limited,amongst others.
Global Prostate Cancer Diagnostics Market:
By Type
- Screening Tests
- Digital rectal exam (DRE)
- Prostate-specific antigen (PSA) test
- Confirmatory Tests
- PCA3Test
- Transrectal Ultrasound
- Prostate Biopsy
- MRI Fusion
- Blood-based assay
- Others
By Cancer types
- Acinar Adenocarcinoma
- Ductal Adenocarcinoma
- Transitional Cell (Or Urothelial) Cancer
- Squamous Cell Cancer
- Small Cell Prostate Cancer
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East and Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2013 - 2017
1.2.2. Base Year: 2018
1.2.3. Forecast Years: 2019 – 2027
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Prostate Cancer
Diagnostics Market
6. Market Synopsis: Prostate Cancer Diagnostics Market
7. Prostate Cancer Diagnostics Market Analysis:
Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in Prostate Cancer Diagnostics Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Prostate Cancer Diagnostics Market
7.6. Analysis of CPVID-19 impact on Prostate
Cancer Diagnostics Market
8. Global Prostate Cancer Diagnostics Market
Analysis and Forecasts, 2019 – 2027
8.1. Overview
8.1.1. Global Prostate Cancer Diagnostics Market
Revenue (US$ Mn)
8.2. Global Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
8.2.1. Screening Tests (Definition, Market
Estimation and Penetration, 2013 – 2018, Market Estimation (2013 – 2018),
Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional
Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin
America) and Information on Digital rectal exam (DRE), Prostate-specific
antigen (PSA) test)
8.2.1.1. Digital rectal exam (DRE)
8.2.1.2. Prostate-specific antigen (PSA) test
8.2.2. Confirmatory Tests (Definition, Market
Estimation and Penetration, 2013 – 2018, Market Estimation (2013 – 2018),
Market Forecast (2019 – 2027), Compound Annual Growth Rate (CAGR), Regional
Bifurcation (North America, Europe, Asia Pacific, Middle East and Africa, Latin
America) and Information on PCA3Test, Transrectal Ultrasound, Prostate Biopsy,
MRI Fusion)
8.2.2.1. PCA3Test
8.2.2.2. Transrectal Ultrasound
8.2.2.3. Prostate Biopsy
8.2.2.4. MRI Fusion
8.2.3. Blood-based assay
8.2.3.1. Definition
8.2.3.2. Market Estimation and Penetration, 2013 –
2018
8.2.3.3. Market Forecast, 2019 – 2027
8.2.3.4. Compound Annual Growth Rate (CAGR)
8.2.3.5. Regional Bifurcation
8.2.3.5.1. North America
8.2.3.5.1.1. Market Estimation, 2013 – 2018
8.2.3.5.1.2. Market Forecast, 2019 – 2027
8.2.3.5.2. Europe
8.2.3.5.2.1. Market Estimation, 2013 – 2018
8.2.3.5.2.2. Market Forecast, 2019 – 2027
8.2.3.5.3. Asia Pacific
8.2.3.5.3.1. Market Estimation, 2013 – 2018
8.2.3.5.3.2. Market Forecast, 2019 – 2027
8.2.3.5.4. Middle East and Africa
8.2.3.5.4.1. Market Estimation, 2013 – 2018
8.2.3.5.4.2. Market Forecast, 2019 – 2027
8.2.3.5.5. Latin America
8.2.3.5.5.1. Market Estimation, 2013 – 2018
8.2.3.5.5.2. Market Forecast, 2019 – 2027
8.2.4. Others
8.2.4.1. Definition
8.2.4.2. Market Estimation and Penetration, 2013 – 2018
8.2.4.3. Market Forecast, 2019 – 2027
8.2.4.4. Compound Annual Growth Rate (CAGR)
8.2.4.5. Regional Bifurcation
8.2.4.5.1. North America
8.2.4.5.1.1. Market Estimation, 2013 – 2018
8.2.4.5.1.2. Market Forecast, 2019 – 2027
8.2.4.5.2. Europe
8.2.4.5.2.1. Market Estimation, 2013 – 2018
8.2.4.5.2.2. Market Forecast, 2019 – 2027
8.2.4.5.3. Asia Pacific
8.2.4.5.3.1. Market Estimation, 2013 – 2018
8.2.4.5.3.2. Market Forecast, 2019 – 2027
8.2.4.5.4. Middle East and Africa
8.2.4.5.4.1. Market Estimation, 2013 – 2018
8.2.4.5.4.2. Market Forecast, 2019 – 2027
8.2.4.5.5. Latin America
8.2.4.5.5.1. Market Estimation, 2013 – 2018
8.2.4.5.5.2. Market Forecast, 2019 – 2027
8.3. Key Segment for Channeling Investments
8.3.1. By Type
9. Global Prostate Cancer Diagnostics Market
Analysis and Forecasts, 2019 – 2027
9.1. Overview
9.2. Global Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
9.2.1. Acinar Adenocarcinoma
9.2.1.1. Definition
9.2.1.2. Market Estimation and Penetration, 2013 –
2018
9.2.1.3. Market Forecast, 2019 – 2027
9.2.1.4. Compound Annual Growth Rate (CAGR)
9.2.1.5. Regional Bifurcation
9.2.1.5.1. North America
9.2.1.5.1.1. Market Estimation, 2013 – 2018
9.2.1.5.1.2. Market Forecast, 2019 – 2027
9.2.1.5.2. Europe
9.2.1.5.2.1. Market Estimation, 2013 – 2018
9.2.1.5.2.2. Market Forecast, 2019 – 2027
9.2.1.5.3. Asia Pacific
9.2.1.5.3.1. Market Estimation, 2013 – 2018
9.2.1.5.3.2. Market Forecast, 2019 – 2027
9.2.1.5.4. Middle East and Africa
9.2.1.5.4.1. Market Estimation, 2013 – 2018
9.2.1.5.4.2. Market Forecast, 2019 – 2027
9.2.1.5.5. Latin America
9.2.1.5.5.1. Market Estimation, 2013 – 2018
9.2.1.5.5.2. Market Forecast, 2019 – 2027
9.2.2. Ductal Adenocarcinoma
9.2.2.1. Definition
9.2.2.2. Market Estimation and Penetration, 2013 –
2018
9.2.2.3. Market Forecast, 2019 – 2027
9.2.2.4. Compound Annual Growth Rate (CAGR)
9.2.2.5. Regional Bifurcation
9.2.2.5.1. North America
9.2.2.5.1.1. Market Estimation, 2013 – 2018
9.2.2.5.1.2. Market Forecast, 2019 – 2027
9.2.2.5.2. Europe
9.2.2.5.2.1. Market Estimation, 2013 – 2018
9.2.2.5.2.2. Market Forecast, 2019 – 2027
9.2.2.5.3. Asia Pacific
9.2.2.5.3.1. Market Estimation, 2013 – 2018
9.2.2.5.3.2. Market Forecast, 2019 – 2027
9.2.2.5.4. Middle East and Africa
9.2.2.5.4.1. Market Estimation, 2013 – 2018
9.2.2.5.4.2. Market Forecast, 2019 – 2027
9.2.2.5.5. Latin America
9.2.2.5.5.1. Market Estimation, 2013 – 2018
9.2.2.5.5.2. Market Forecast, 2019 – 2027
9.2.3. Transitional Cell (Or Urothelial) Cancer
9.2.3.1. Definition
9.2.3.2. Market Estimation and Penetration, 2013 –
2018
9.2.3.3. Market Forecast, 2019 – 2027
9.2.3.4. Compound Annual Growth Rate (CAGR)
9.2.3.5. Regional Bifurcation
9.2.3.5.1. North America
9.2.3.5.1.1. Market Estimation, 2013 – 2018
9.2.3.5.1.2. Market Forecast, 2019 – 2027
9.2.3.5.2. Europe
9.2.3.5.2.1. Market Estimation, 2013 – 2018
9.2.3.5.2.2. Market Forecast, 2019 – 2027
9.2.3.5.3. Asia Pacific
9.2.3.5.3.1. Market Estimation, 2013 – 2018
9.2.3.5.3.2. Market Forecast, 2019 – 2027
9.2.3.5.4. Middle East and Africa
9.2.3.5.4.1. Market Estimation, 2013 – 2018
9.2.3.5.4.2. Market Forecast, 2019 – 2027
9.2.3.5.5. Latin America
9.2.3.5.5.1. Market Estimation, 2013 – 2018
9.2.3.5.5.2. Market Forecast, 2019 – 2027
9.2.4. Squamous Cell Cancer
9.2.4.1. Definition
9.2.4.2. Market Estimation and Penetration, 2013 –
2018
9.2.4.3. Market Forecast, 2019 – 2027
9.2.4.4. Compound Annual Growth Rate (CAGR)
9.2.4.5. Regional Bifurcation
9.2.4.5.1. North America
9.2.4.5.1.1. Market Estimation, 2013 – 2018
9.2.4.5.1.2. Market Forecast, 2019 – 2027
9.2.4.5.2. Europe
9.2.4.5.2.1. Market Estimation, 2013 – 2018
9.2.4.5.2.2. Market Forecast, 2019 – 2027
9.2.4.5.3. Asia Pacific
9.2.4.5.3.1. Market Estimation, 2013 – 2018
9.2.4.5.3.2. Market Forecast, 2019 – 2027
9.2.4.5.4. Middle East and Africa
9.2.4.5.4.1. Market Estimation, 2013 – 2018
9.2.4.5.4.2. Market Forecast, 2019 – 2027
9.2.4.5.5. Latin America
9.2.4.5.5.1. Market Estimation, 2013 – 2018
9.2.4.5.5.2. Market Forecast, 2019 – 2027
9.2.5. Small Cell Prostate Cancer
9.2.5.1. Definition
9.2.5.2. Market Estimation and Penetration, 2013 –
2018
9.2.5.3. Market Forecast, 2019 – 2027
9.2.5.4. Compound Annual Growth Rate (CAGR)
9.2.5.5. Regional Bifurcation
9.2.5.5.1. North America
9.2.5.5.1.1. Market Estimation, 2013 – 2018
9.2.5.5.1.2. Market Forecast, 2019 – 2027
9.2.5.5.2. Europe
9.2.5.5.2.1. Market Estimation, 2013 – 2018
9.2.5.5.2.2. Market Forecast, 2019 – 2027
9.2.5.5.3. Asia Pacific
9.2.5.5.3.1. Market Estimation, 2013 – 2018
9.2.5.5.3.2. Market Forecast, 2019 – 2027
9.2.5.5.4. Middle East and Africa
9.2.5.5.4.1. Market Estimation, 2013 – 2018
9.2.5.5.4.2. Market Forecast, 2019 – 2027
9.2.5.5.5. Latin America
9.2.5.5.5.1. Market Estimation, 2013 – 2018
9.2.5.5.5.2. Market Forecast, 2019 – 2027
9.3. Key Segment for Channeling Investments
9.3.1. By Cancer types
10. North America Prostate Cancer Diagnostics
Market Analysis and Forecasts, 2019 - 2027
10.1. Overview
10.1.1. North America Prostate Cancer Diagnostics
Market Revenue (US$ Mn)
10.2. North America Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Type
10.2.1. Screening Tests
10.2.1.1. Digital rectal exam (DRE)
10.2.1.2. Prostate-specific antigen (PSA) test
10.2.2. Confirmatory Tests
10.2.2.1. PCA3Test
10.2.2.2. Transrectal Ultrasound
10.2.2.3. Prostate Biopsy
10.2.2.4. MRI Fusion
10.2.3. Blood-based assay
10.2.4. Others
10.3. North America Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Cancer types
10.3.1. Acinar Adenocarcinoma
10.3.2. Ductal Adenocarcinoma
10.3.3. Transitional Cell (Or Urothelial) Cancer
10.3.4. Squamous Cell Cancer
10.3.5. Small Cell Prostate Cancer
10.4. North America Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Country
10.4.1. U.S
10.4.1.1. U.S Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
10.4.1.1.1. Screening Tests
10.4.1.1.1.1. Digital rectal exam (DRE)
10.4.1.1.1.2. Prostate-specific antigen (PSA) test
10.4.1.1.2. Confirmatory Tests
10.4.1.1.2.1. PCA3Test
10.4.1.1.2.2. Transrectal Ultrasound
10.4.1.1.2.3. Prostate Biopsy
10.4.1.1.2.4. MRI Fusion
10.4.1.1.3. Blood-based assay
10.4.1.1.4. Others
10.4.1.2. U.S Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
10.4.1.2.1. Acinar Adenocarcinoma
10.4.1.2.2. Ductal Adenocarcinoma
10.4.1.2.3. Transitional Cell (Or Urothelial) Cancer
10.4.1.2.4. Squamous Cell Cancer
10.4.1.2.5. Small Cell Prostate Cancer
10.4.2. Canada
10.4.2.1. Canada Prostate Cancer Diagnostics Market Revenue
(US$ Mn) and Forecasts, By Type
10.4.2.1.1. Screening Tests
10.4.2.1.1.1. Digital rectal exam (DRE)
10.4.2.1.1.2. Prostate-specific antigen (PSA) test
10.4.2.1.2. Confirmatory Tests
10.4.2.1.2.1. PCA3Test
10.4.2.1.2.2. Transrectal Ultrasound
10.4.2.1.2.3. Prostate Biopsy
10.4.2.1.2.4. MRI Fusion
10.4.2.1.3. Blood-based assay
10.4.2.1.4. Others
10.4.2.2. Canada Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
10.4.2.2.1. Acinar Adenocarcinoma
10.4.2.2.2. Ductal Adenocarcinoma
10.4.2.2.3. Transitional Cell (Or Urothelial) Cancer
10.4.2.2.4. Squamous Cell Cancer
10.4.2.2.5. Small Cell Prostate Cancer
10.4.3. Mexico
10.4.3.1. Mexico Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
10.4.3.1.1. Screening Tests
10.4.3.1.1.1. Digital rectal exam (DRE)
10.4.3.1.1.2. Prostate-specific antigen (PSA) test
10.4.3.1.2. Confirmatory Tests
10.4.3.1.2.1. PCA3Test
10.4.3.1.2.2. Transrectal Ultrasound
10.4.3.1.2.3. Prostate Biopsy
10.4.3.1.2.4. MRI Fusion
10.4.3.1.3. Blood-based assay
10.4.3.1.4. Others
10.4.3.2. Mexico Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
10.4.3.2.1. Acinar Adenocarcinoma
10.4.3.2.2. Ductal Adenocarcinoma
10.4.3.2.3. Transitional Cell (Or Urothelial) Cancer
10.4.3.2.4. Squamous Cell Cancer
10.4.3.2.5. Small Cell Prostate Cancer
10.4.4. Rest of North America
10.4.4.1. Rest of North America Prostate Cancer
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Type
10.4.4.1.1. Screening Tests
10.4.4.1.1.1. Digital rectal exam (DRE)
10.4.4.1.1.2. Prostate-specific antigen (PSA) test
10.4.4.1.2. Confirmatory Tests
10.4.4.1.2.1. PCA3Test
10.4.4.1.2.2. Transrectal Ultrasound
10.4.4.1.2.3. Prostate Biopsy
10.4.4.1.2.4. MRI Fusion
10.4.4.1.3. Blood-based assay
10.4.4.1.4. Others
10.4.4.2. Rest of North America Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Cancer types
10.4.4.2.1. Acinar Adenocarcinoma
10.4.4.2.2. Ductal Adenocarcinoma
10.4.4.2.3. Transitional Cell (Or Urothelial) Cancer
10.4.4.2.4. Squamous Cell Cancer
10.4.4.2.5. Small Cell Prostate Cancer
10.5. Key Segment for Channeling Investments
10.5.1. By Country
10.5.2. By Type
10.5.3. By Cancer types
11. Europe Prostate Cancer Diagnostics Market
Analysis and Forecasts, 2019 - 2027
11.1. Overview
11.1.1. Europe Prostate Cancer Diagnostics Market
Revenue (US$ Mn)
11.2. Europe Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
11.2.1. Screening Tests
11.2.1.1. Digital rectal exam (DRE)
11.2.1.2. Prostate-specific antigen (PSA) test
11.2.2. Confirmatory Tests
11.2.2.1. PCA3Test
11.2.2.2. Transrectal Ultrasound
11.2.2.3. Prostate Biopsy
11.2.2.4. MRI Fusion
11.2.3. Blood-based assay
11.2.4. Others
11.3. Europe Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
11.3.1. Acinar Adenocarcinoma
11.3.2. Ductal Adenocarcinoma
11.3.3. Transitional Cell (Or Urothelial) Cancer
11.3.4. Squamous Cell Cancer
11.3.5. Small Cell Prostate Cancer
11.4. Europe Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Country
11.4.1. France
11.4.1.1. France Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
11.4.1.1.1. Screening Tests
11.4.1.1.1.1. Digital rectal exam (DRE)
11.4.1.1.1.2. Prostate-specific antigen (PSA) test
11.4.1.1.2. Confirmatory Tests
11.4.1.1.2.1. PCA3Test
11.4.1.1.2.2. Transrectal Ultrasound
11.4.1.1.2.3. Prostate Biopsy
11.4.1.1.2.4. MRI Fusion
11.4.1.1.3. Blood-based assay
11.4.1.1.4. Others
11.4.1.2. France Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
11.4.1.2.1. Acinar Adenocarcinoma
11.4.1.2.2. Ductal Adenocarcinoma
11.4.1.2.3. Transitional Cell (Or Urothelial) Cancer
11.4.1.2.4. Squamous Cell Cancer
11.4.1.2.5. Small Cell Prostate Cancer
11.4.2. The UK
11.4.2.1. The UK Prostate Cancer Diagnostics Market Revenue
(US$ Mn) and Forecasts, By Type
11.4.2.1.1. Screening Tests
11.4.2.1.1.1. Digital rectal exam (DRE)
11.4.2.1.1.2. Prostate-specific antigen (PSA) test
11.4.2.1.2. Confirmatory Tests
11.4.2.1.2.1. PCA3Test
11.4.2.1.2.2. Transrectal Ultrasound
11.4.2.1.2.3. Prostate Biopsy
11.4.2.1.2.4. MRI Fusion
11.4.2.1.3. Blood-based assay
11.4.2.1.4. Others
11.4.2.2. The UK Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
11.4.2.2.1. Acinar Adenocarcinoma
11.4.2.2.2. Ductal Adenocarcinoma
11.4.2.2.3. Transitional Cell (Or Urothelial) Cancer
11.4.2.2.4. Squamous Cell Cancer
11.4.2.2.5. Small Cell Prostate Cancer
11.4.3. Spain
11.4.3.1. Spain Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
11.4.3.1.1. Screening Tests
11.4.3.1.1.1. Digital rectal exam (DRE)
11.4.3.1.1.2. Prostate-specific antigen (PSA) test
11.4.3.1.2. Confirmatory Tests
11.4.3.1.2.1. PCA3Test
11.4.3.1.2.2. Transrectal Ultrasound
11.4.3.1.2.3. Prostate Biopsy
11.4.3.1.2.4. MRI Fusion
11.4.3.1.3. Blood-based assay
11.4.3.1.4. Others
11.4.3.2. Spain Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
11.4.3.2.1. Acinar Adenocarcinoma
11.4.3.2.2. Ductal Adenocarcinoma
11.4.3.2.3. Transitional Cell (Or Urothelial) Cancer
11.4.3.2.4. Squamous Cell Cancer
11.4.3.2.5. Small Cell Prostate Cancer
11.4.4. Germany
11.4.4.1. Germany Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
11.4.4.1.1. Screening Tests
11.4.4.1.1.1. Digital rectal exam (DRE)
11.4.4.1.1.2. Prostate-specific antigen (PSA) test
11.4.4.1.2. Confirmatory Tests
11.4.4.1.2.1. PCA3Test
11.4.4.1.2.2. Transrectal Ultrasound
11.4.4.1.2.3. Prostate Biopsy
11.4.4.1.2.4. MRI Fusion
11.4.4.1.3. Blood-based assay
11.4.4.1.4. Others
11.4.4.2. Germany Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
11.4.4.2.1. Acinar Adenocarcinoma
11.4.4.2.2. Ductal Adenocarcinoma
11.4.4.2.3. Transitional Cell (Or Urothelial) Cancer
11.4.4.2.4. Squamous Cell Cancer
11.4.4.2.5. Small Cell Prostate Cancer
11.4.5. Italy
11.4.5.1. Italy Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
11.4.5.1.1. Screening Tests
11.4.5.1.1.1. Digital rectal exam (DRE)
11.4.5.1.1.2. Prostate-specific antigen (PSA) test
11.4.5.1.2. Confirmatory Tests
11.4.5.1.2.1. PCA3Test
11.4.5.1.2.2. Transrectal Ultrasound
11.4.5.1.2.3. Prostate Biopsy
11.4.5.1.2.4. MRI Fusion
11.4.5.1.3. Blood-based assay
11.4.5.1.4. Others
11.4.5.2. Italy Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
11.4.5.2.1. Acinar Adenocarcinoma
11.4.5.2.2. Ductal Adenocarcinoma
11.4.5.2.3. Transitional Cell (Or Urothelial) Cancer
11.4.5.2.4. Squamous Cell Cancer
11.4.5.2.5. Small Cell Prostate Cancer
11.4.6. Nordic Countries
11.4.6.1. Nordic Countries Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Type
11.4.6.1.1. Screening Tests
11.4.6.1.1.1. Digital rectal exam (DRE)
11.4.6.1.1.2. Prostate-specific antigen (PSA) test
11.4.6.1.2. Confirmatory Tests
11.4.6.1.2.1. PCA3Test
11.4.6.1.2.2. Transrectal Ultrasound
11.4.6.1.2.3. Prostate Biopsy
11.4.6.1.2.4. MRI Fusion
11.4.6.1.3. Blood-based assay
11.4.6.1.4. Others
11.4.6.2. Nordic Countries Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Cancer types
11.4.6.2.1. Acinar Adenocarcinoma
11.4.6.2.2. Ductal Adenocarcinoma
11.4.6.2.3. Transitional Cell (Or Urothelial) Cancer
11.4.6.2.4. Squamous Cell Cancer
11.4.6.2.5. Small Cell Prostate Cancer
11.4.6.3. Nordic Countries Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Country
11.4.6.3.1. Denmark
11.4.6.3.2. Finland
11.4.6.3.3. Iceland
11.4.6.3.4. Sweden
11.4.6.3.5. Norway
11.4.7. Benelux Union
11.4.7.1. Benelux Union Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Type
11.4.7.1.1. Screening Tests
11.4.7.1.1.1. Digital rectal exam (DRE)
11.4.7.1.1.2. Prostate-specific antigen (PSA) test
11.4.7.1.2. Confirmatory Tests
11.4.7.1.2.1. PCA3Test
11.4.7.1.2.2. Transrectal Ultrasound
11.4.7.1.2.3. Prostate Biopsy
11.4.7.1.2.4. MRI Fusion
11.4.7.1.3. Blood-based assay
11.4.7.1.4. Others
11.4.7.2. Benelux Union Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Cancer types
11.4.7.2.1. Acinar Adenocarcinoma
11.4.7.2.2. Ductal Adenocarcinoma
11.4.7.2.3. Transitional Cell (Or Urothelial) Cancer
11.4.7.2.4. Squamous Cell Cancer
11.4.7.2.5. Small Cell Prostate Cancer
11.4.7.3. Benelux Union Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Country
11.4.7.3.1. Belgium
11.4.7.3.2. The Netherlands
11.4.7.3.3. Luxembourg
11.4.8. Rest of Europe
11.4.8.1. Rest of Europe Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Type
11.4.8.1.1. Screening Tests
11.4.8.1.1.1. Digital rectal exam (DRE)
11.4.8.1.1.2. Prostate-specific antigen (PSA) test
11.4.8.1.2. Confirmatory Tests
11.4.8.1.2.1. PCA3Test
11.4.8.1.2.2. Transrectal Ultrasound
11.4.8.1.2.3. Prostate Biopsy
11.4.8.1.2.4. MRI Fusion
11.4.8.1.3. Blood-based assay
11.4.8.1.4. Others
11.4.8.2. Rest of Europe Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Cancer types
11.4.8.2.1. Acinar Adenocarcinoma
11.4.8.2.2. Ductal Adenocarcinoma
11.4.8.2.3. Transitional Cell (Or Urothelial) Cancer
11.4.8.2.4. Squamous Cell Cancer
11.4.8.2.5. Small Cell Prostate Cancer
11.5. Key Segment for Channeling Investments
11.5.1. By Country
11.5.2. By Type
11.5.3. By Cancer types
12. Asia Pacific Prostate Cancer Diagnostics
Market Analysis and Forecasts, 2019 - 2027
12.1. Overview
12.1.1. Asia Pacific Prostate Cancer Diagnostics
Market Revenue (US$ Mn)
12.2. Asia Pacific Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Type
12.2.1. Screening Tests
12.2.1.1. Digital rectal exam (DRE)
12.2.1.2. Prostate-specific antigen (PSA) test
12.2.2. Confirmatory Tests
12.2.2.1. PCA3Test
12.2.2.2. Transrectal Ultrasound
12.2.2.3. Prostate Biopsy
12.2.2.4. MRI Fusion
12.2.3. Blood-based assay
12.2.4. Others
12.3. Asia Pacific Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Cancer types
12.3.1. Acinar Adenocarcinoma
12.3.2. Ductal Adenocarcinoma
12.3.3. Transitional Cell (Or Urothelial) Cancer
12.3.4. Squamous Cell Cancer
12.3.5. Small Cell Prostate Cancer
12.4. Asia Pacific Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Country
12.4.1. China
12.4.1.1. China Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
12.4.1.1.1. Screening Tests
12.4.1.1.1.1. Digital rectal exam (DRE)
12.4.1.1.1.2. Prostate-specific antigen (PSA) test
12.4.1.1.2. Confirmatory Tests
12.4.1.1.2.1. PCA3Test
12.4.1.1.2.2. Transrectal Ultrasound
12.4.1.1.2.3. Prostate Biopsy
12.4.1.1.2.4. MRI Fusion
12.4.1.1.3. Blood-based assay
12.4.1.1.4. Others
12.4.1.2. China Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
12.4.1.2.1. Acinar Adenocarcinoma
12.4.1.2.2. Ductal Adenocarcinoma
12.4.1.2.3. Transitional Cell (Or Urothelial) Cancer
12.4.1.2.4. Squamous Cell Cancer
12.4.1.2.5. Small Cell Prostate Cancer
12.4.2. Japan
12.4.2.1. Japan Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
12.4.2.1.1. Screening Tests
12.4.2.1.1.1. Digital rectal exam (DRE)
12.4.2.1.1.2. Prostate-specific antigen (PSA) test
12.4.2.1.2. Confirmatory Tests
12.4.2.1.2.1. PCA3Test
12.4.2.1.2.2. Transrectal Ultrasound
12.4.2.1.2.3. Prostate Biopsy
12.4.2.1.2.4. MRI Fusion
12.4.2.1.3. Blood-based assay
12.4.2.1.4. Others
12.4.2.2. Japan Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
12.4.2.2.1. Acinar Adenocarcinoma
12.4.2.2.2. Ductal Adenocarcinoma
12.4.2.2.3. Transitional Cell (Or Urothelial) Cancer
12.4.2.2.4. Squamous Cell Cancer
12.4.2.2.5. Small Cell Prostate Cancer
12.4.3. India
12.4.3.1. India Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
12.4.3.1.1. Screening Tests
12.4.3.1.1.1. Digital rectal exam (DRE)
12.4.3.1.1.2. Prostate-specific antigen (PSA) test
12.4.3.1.2. Confirmatory Tests
12.4.3.1.2.1. PCA3Test
12.4.3.1.2.2. Transrectal Ultrasound
12.4.3.1.2.3. Prostate Biopsy
12.4.3.1.2.4. MRI Fusion
12.4.3.1.3. Blood-based assay
12.4.3.1.4. Others
12.4.3.2. India Prostate Cancer Diagnostics Market Revenue
(US$ Mn) and Forecasts, By Cancer types
12.4.3.2.1. Acinar Adenocarcinoma
12.4.3.2.2. Ductal Adenocarcinoma
12.4.3.2.3. Transitional Cell (Or Urothelial) Cancer
12.4.3.2.4. Squamous Cell Cancer
12.4.3.2.5. Small Cell Prostate Cancer
12.4.4. New Zealand
12.4.4.1. New Zealand Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Type
12.4.4.1.1. Screening Tests
12.4.4.1.1.1. Digital rectal exam (DRE)
12.4.4.1.1.2. Prostate-specific antigen (PSA) test
12.4.4.1.2. Confirmatory Tests
12.4.4.1.2.1. PCA3Test
12.4.4.1.2.2. Transrectal Ultrasound
12.4.4.1.2.3. Prostate Biopsy
12.4.4.1.2.4. MRI Fusion
12.4.4.1.3. Blood-based assay
12.4.4.1.4. Others
12.4.4.2. New Zealand Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Cancer types
12.4.4.2.1. Acinar Adenocarcinoma
12.4.4.2.2. Ductal Adenocarcinoma
12.4.4.2.3. Transitional Cell (Or Urothelial) Cancer
12.4.4.2.4. Squamous Cell Cancer
12.4.4.2.5. Small Cell Prostate Cancer
12.4.5. Australia
12.4.5.1. Australia Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
12.4.5.1.1. Screening Tests
12.4.5.1.1.1. Digital rectal exam (DRE)
12.4.5.1.1.2. Prostate-specific antigen (PSA) test
12.4.5.1.2. Confirmatory Tests
12.4.5.1.2.1. PCA3Test
12.4.5.1.2.2. Transrectal Ultrasound
12.4.5.1.2.3. Prostate Biopsy
12.4.5.1.2.4. MRI Fusion
12.4.5.1.3. Blood-based assay
12.4.5.1.4. Others
12.4.5.2. Australia Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
12.4.5.2.1. Acinar Adenocarcinoma
12.4.5.2.2. Ductal Adenocarcinoma
12.4.5.2.3. Transitional Cell (Or Urothelial) Cancer
12.4.5.2.4. Squamous Cell Cancer
12.4.5.2.5. Small Cell Prostate Cancer
12.4.6. South Korea
12.4.6.1. South Korea Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Type
12.4.6.1.1. Screening Tests
12.4.6.1.1.1. Digital rectal exam (DRE)
12.4.6.1.1.2. Prostate-specific antigen (PSA) test
12.4.6.1.2. Confirmatory Tests
12.4.6.1.2.1. PCA3Test
12.4.6.1.2.2. Transrectal Ultrasound
12.4.6.1.2.3. Prostate Biopsy
12.4.6.1.2.4. MRI Fusion
12.4.6.1.3. Blood-based assay
12.4.6.1.4. Others
12.4.6.2. South Korea Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Cancer types
12.4.6.2.1. Acinar Adenocarcinoma
12.4.6.2.2. Ductal Adenocarcinoma
12.4.6.2.3. Transitional Cell (Or Urothelial) Cancer
12.4.6.2.4. Squamous Cell Cancer
12.4.6.2.5. Small Cell Prostate Cancer
12.4.7. Southeast Asia
12.4.7.1. Southeast Asia Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Type
12.4.7.1.1. Screening Tests
12.4.7.1.1.1. Digital rectal exam (DRE)
12.4.7.1.1.2. Prostate-specific antigen (PSA) test
12.4.7.1.2. Confirmatory Tests
12.4.7.1.2.1. PCA3Test
12.4.7.1.2.2. Transrectal Ultrasound
12.4.7.1.2.3. Prostate Biopsy
12.4.7.1.2.4. MRI Fusion
12.4.7.1.3. Blood-based assay
12.4.7.1.4. Others
12.4.7.2. Southeast Asia Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Cancer types
12.4.7.2.1. Acinar Adenocarcinoma
12.4.7.2.2. Ductal Adenocarcinoma
12.4.7.2.3. Transitional Cell (Or Urothelial) Cancer
12.4.7.2.4. Squamous Cell Cancer
12.4.7.2.5. Small Cell Prostate Cancer
12.4.7.3. Southeast Asia Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Country
12.4.7.3.1. Indonesia
12.4.7.3.2. Thailand
12.4.7.3.3. Malaysia
12.4.7.3.4. Singapore
12.4.7.3.5. Rest of Southeast Asia
12.4.8. Rest of Asia Pacific
12.4.8.1. Rest of Asia Pacific Prostate Cancer
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Type
12.4.8.1.1. Screening Tests
12.4.8.1.1.1. Digital rectal exam (DRE)
12.4.8.1.1.2. Prostate-specific antigen (PSA) test
12.4.8.1.2. Confirmatory Tests
12.4.8.1.2.1. PCA3Test
12.4.8.1.2.2. Transrectal Ultrasound
12.4.8.1.2.3. Prostate Biopsy
12.4.8.1.2.4. MRI Fusion
12.4.8.1.3. Blood-based assay
12.4.8.1.4. Others
12.4.8.2. Rest of Asia Pacific Prostate Cancer
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Cancer types
12.4.8.2.1. Acinar Adenocarcinoma
12.4.8.2.2. Ductal Adenocarcinoma
12.4.8.2.3. Transitional Cell (Or Urothelial) Cancer
12.4.8.2.4. Squamous Cell Cancer
12.4.8.2.5. Small Cell Prostate Cancer
12.5. Key Segment for Channeling Investments
12.5.1. By Country
12.5.2. By Type
12.5.3. By Cancer types
13. Middle East and Africa Prostate Cancer
Diagnostics Market Analysis and Forecasts, 2019 - 2027
13.1. Overview
13.1.1. Middle East and Africa Prostate Cancer
Diagnostics Market Revenue (US$ Mn)
13.2. Middle East and Africa Prostate Cancer
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Type
13.2.1. Screening Tests
13.2.1.1. Digital rectal exam (DRE)
13.2.1.2. Prostate-specific antigen (PSA) test
13.2.2. Confirmatory Tests
13.2.2.1. PCA3Test
13.2.2.2. Transrectal Ultrasound
13.2.2.3. Prostate Biopsy
13.2.2.4. MRI Fusion
13.2.3. Blood-based assay
13.2.4. Others
13.3. Middle East and Africa Prostate Cancer
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Cancer types
13.3.1. Acinar Adenocarcinoma
13.3.2. Ductal Adenocarcinoma
13.3.3. Transitional Cell (Or Urothelial) Cancer
13.3.4. Squamous Cell Cancer
13.3.5. Small Cell Prostate Cancer
13.4. Middle East and Africa Prostate Cancer
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Country
13.4.1. Saudi Arabia
13.4.1.1. Saudi Arabia Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Type
13.4.1.1.1. Screening Tests
13.4.1.1.1.1. Digital rectal exam (DRE)
13.4.1.1.1.2. Prostate-specific antigen (PSA) test
13.4.1.1.2. Confirmatory Tests
13.4.1.1.2.1. PCA3Test
13.4.1.1.2.2. Transrectal Ultrasound
13.4.1.1.2.3. Prostate Biopsy
13.4.1.1.2.4. MRI Fusion
13.4.1.1.3. Blood-based assay
13.4.1.1.4. Others
13.4.1.2. Saudi Arabia Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Cancer types
13.4.1.2.1. Acinar Adenocarcinoma
13.4.1.2.2. Ductal Adenocarcinoma
13.4.1.2.3. Transitional Cell (Or Urothelial) Cancer
13.4.1.2.4. Squamous Cell Cancer
13.4.1.2.5. Small Cell Prostate Cancer
13.4.2. UAE
13.4.2.1. UAE Prostate Cancer Diagnostics Market Revenue
(US$ Mn) and Forecasts, By Type
13.4.2.1.1. Screening Tests
13.4.2.1.1.1. Digital rectal exam (DRE)
13.4.2.1.1.2. Prostate-specific antigen (PSA) test
13.4.2.1.2. Confirmatory Tests
13.4.2.1.2.1. PCA3Test
13.4.2.1.2.2. Transrectal Ultrasound
13.4.2.1.2.3. Prostate Biopsy
13.4.2.1.2.4. MRI Fusion
13.4.2.1.3. Blood-based assay
13.4.2.1.4. Others
13.4.2.2. UAE Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
13.4.2.2.1. Acinar Adenocarcinoma
13.4.2.2.2. Ductal Adenocarcinoma
13.4.2.2.3. Transitional Cell (Or Urothelial) Cancer
13.4.2.2.4. Squamous Cell Cancer
13.4.2.2.5. Small Cell Prostate Cancer
13.4.3. Egypt
13.4.3.1. Egypt Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
13.4.3.1.1. Screening Tests
13.4.3.1.1.1. Digital rectal exam (DRE)
13.4.3.1.1.2. Prostate-specific antigen (PSA) test
13.4.3.1.2. Confirmatory Tests
13.4.3.1.2.1. PCA3Test
13.4.3.1.2.2. Transrectal Ultrasound
13.4.3.1.2.3. Prostate Biopsy
13.4.3.1.2.4. MRI Fusion
13.4.3.1.3. Blood-based assay
13.4.3.1.4. Others
13.4.3.2. Egypt Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
13.4.3.2.1. Acinar Adenocarcinoma
13.4.3.2.2. Ductal Adenocarcinoma
13.4.3.2.3. Transitional Cell (Or Urothelial) Cancer
13.4.3.2.4. Squamous Cell Cancer
13.4.3.2.5. Small Cell Prostate Cancer
13.4.4. Kuwait
13.4.4.1. Kuwait Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
13.4.4.1.1. Screening Tests
13.4.4.1.1.1. Digital rectal exam (DRE)
13.4.4.1.1.2. Prostate-specific antigen (PSA) test
13.4.4.1.2. Confirmatory Tests
13.4.4.1.2.1. PCA3Test
13.4.4.1.2.2. Transrectal Ultrasound
13.4.4.1.2.3. Prostate Biopsy
13.4.4.1.2.4. MRI Fusion
13.4.4.1.3. Blood-based assay
13.4.4.1.4. Others
13.4.4.2. Kuwait Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
13.4.4.2.1. Acinar Adenocarcinoma
13.4.4.2.2. Ductal Adenocarcinoma
13.4.4.2.3. Transitional Cell (Or Urothelial) Cancer
13.4.4.2.4. Squamous Cell Cancer
13.4.4.2.5. Small Cell Prostate Cancer
13.4.5. South Africa
13.4.5.1. South Africa Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Type
13.4.5.1.1. Screening Tests
13.4.5.1.1.1. Digital rectal exam (DRE)
13.4.5.1.1.2. Prostate-specific antigen (PSA) test
13.4.5.1.2. Confirmatory Tests
13.4.5.1.2.1. PCA3Test
13.4.5.1.2.2. Transrectal Ultrasound
13.4.5.1.2.3. Prostate Biopsy
13.4.5.1.2.4. MRI Fusion
13.4.5.1.3. Blood-based assay
13.4.5.1.4. Others
13.4.5.2. South Africa Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Cancer types
13.4.5.2.1. Acinar Adenocarcinoma
13.4.5.2.2. Ductal Adenocarcinoma
13.4.5.2.3. Transitional Cell (Or Urothelial) Cancer
13.4.5.2.4. Squamous Cell Cancer
13.4.5.2.5. Small Cell Prostate Cancer
13.4.6. Rest of Middle East & Africa
13.4.6.1. Rest of Middle East & Africa Prostate
Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Type
13.4.6.1.1. Screening Tests
13.4.6.1.1.1. Digital rectal exam (DRE)
13.4.6.1.1.2. Prostate-specific antigen (PSA) test
13.4.6.1.2. Confirmatory Tests
13.4.6.1.2.1. PCA3Test
13.4.6.1.2.2. Transrectal Ultrasound
13.4.6.1.2.3. Prostate Biopsy
13.4.6.1.2.4. MRI Fusion
13.4.6.1.3. Blood-based assay
13.4.6.1.4. Others
13.4.6.2. Rest of Middle East & Africa Prostate
Cancer Diagnostics Market Revenue (US$ Mn) and Forecasts, By Cancer types
13.4.6.2.1. Acinar Adenocarcinoma
13.4.6.2.2. Ductal Adenocarcinoma
13.4.6.2.3. Transitional Cell (Or Urothelial) Cancer
13.4.6.2.4. Squamous Cell Cancer
13.4.6.2.5. Small Cell Prostate Cancer
13.5. Key Segment for Channeling Investments
13.5.1. By Country
13.5.2. By Type
13.5.3. By Cancer types
14. Latin America Prostate Cancer Diagnostics
Market Analysis and Forecasts, 2019 - 2027
14.1. Overview
14.1.1. Latin America Prostate Cancer Diagnostics
Market Revenue (US$ Mn)
14.2. Latin America Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Type
14.2.1. Screening Tests
14.2.1.1. Digital rectal exam (DRE)
14.2.1.2. Prostate-specific antigen (PSA) test
14.2.2. Confirmatory Tests
14.2.2.1. PCA3Test
14.2.2.2. Transrectal Ultrasound
14.2.2.3. Prostate Biopsy
14.2.2.4. MRI Fusion
14.2.3. Blood-based assay
14.2.4. Others
14.3. Latin America Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Cancer types
14.3.1. Acinar Adenocarcinoma
14.3.2. Ductal Adenocarcinoma
14.3.3. Transitional Cell (Or Urothelial) Cancer
14.3.4. Squamous Cell Cancer
14.3.5. Small Cell Prostate Cancer
14.4. Latin America Prostate Cancer Diagnostics
Market Revenue (US$ Mn) and Forecasts, By Country
14.4.1. Brazil
14.4.1.1. Brazil Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
14.4.1.1.1. Screening Tests
14.4.1.1.1.1. Digital rectal exam (DRE)
14.4.1.1.1.2. Prostate-specific antigen (PSA) test
14.4.1.1.2. Confirmatory Tests
14.4.1.1.2.1. PCA3Test
14.4.1.1.2.2. Transrectal Ultrasound
14.4.1.1.2.3. Prostate Biopsy
14.4.1.1.2.4. MRI Fusion
14.4.1.1.3. Blood-based assay
14.4.1.1.4. Others
14.4.1.2. Brazil Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
14.4.1.2.1. Acinar Adenocarcinoma
14.4.1.2.2. Ductal Adenocarcinoma
14.4.1.2.3. Transitional Cell (Or Urothelial) Cancer
14.4.1.2.4. Squamous Cell Cancer
14.4.1.2.5. Small Cell Prostate Cancer
14.4.2. Argentina
14.4.2.1. Argentina Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Type
14.4.2.1.1. Screening Tests
14.4.2.1.1.1. Digital rectal exam (DRE)
14.4.2.1.1.2. Prostate-specific antigen (PSA) test
14.4.2.1.2. Confirmatory Tests
14.4.2.1.2.1. PCA3Test
14.4.2.1.2.2. Transrectal Ultrasound
14.4.2.1.2.3. Prostate Biopsy
14.4.2.1.2.4. MRI Fusion
14.4.2.1.3. Blood-based assay
14.4.2.1.4. Others
14.4.2.2. Argentina Prostate Cancer Diagnostics Market
Revenue (US$ Mn) and Forecasts, By Cancer types
14.4.2.2.1. Acinar Adenocarcinoma
14.4.2.2.2. Ductal Adenocarcinoma
14.4.2.2.3. Transitional Cell (Or Urothelial) Cancer
14.4.2.2.4. Squamous Cell Cancer
14.4.2.2.5. Small Cell Prostate Cancer
14.4.3. Rest of Latin America
14.4.3.1. Rest of Latin America Prostate Cancer
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Type
14.4.3.1.1. Screening Tests
14.4.3.1.1.1. Digital rectal exam (DRE)
14.4.3.1.1.2. Prostate-specific antigen (PSA) test
14.4.3.1.2. Confirmatory Tests
14.4.3.1.2.1. PCA3Test
14.4.3.1.2.2. Transrectal Ultrasound
14.4.3.1.2.3. Prostate Biopsy
14.4.3.1.2.4. MRI Fusion
14.4.3.1.3. Blood-based assay
14.4.3.1.4. Others
14.4.3.2. Rest of Latin America Prostate Cancer
Diagnostics Market Revenue (US$ Mn) and Forecasts, By Cancer types
14.4.3.2.1. Acinar Adenocarcinoma
14.4.3.2.2. Ductal Adenocarcinoma
14.4.3.2.3. Transitional Cell (Or Urothelial) Cancer
14.4.3.2.4. Squamous Cell Cancer
14.4.3.2.5. Small Cell Prostate Cancer
14.5. Key Segment for Channeling Investments
14.5.1. By Country
14.5.2. By Type
14.5.3. By Cancer types
15. Competitive Benchmarking
15.1. Market Share Analysis, 2018
15.2. Global Presence and Growth Strategies
15.2.1. Mergers and Acquisitions
15.2.2. Product Launches
15.2.3. Investments Trends
15.2.4. R&D Initiatives
16. Player Profiles
16.1. Exosome Diagnostics
16.1.1. Company Details
16.1.2. Company Overview
16.1.3. Product Offerings
16.1.4. Key Developments
16.1.5. Financial Analysis
16.1.6. SWOT Analysis
16.1.7. Business Strategies
16.2. Genomic Health, Inc.
16.2.1. Company Details
16.2.2. Company Overview
16.2.3. Product Offerings
16.2.4. Key Developments
16.2.5. Financial Analysis
16.2.6. SWOT Analysis
16.2.7. Business Strategies
16.3. MDxHealth
16.3.1. Company Details
16.3.2. Company Overview
16.3.3. Product Offerings
16.3.4. Key Developments
16.3.5. Financial Analysis
16.3.6. SWOT Analysis
16.3.7. Business Strategies
16.4. MINOMIC
16.4.1. Company Details
16.4.2. Company Overview
16.4.3. Product Offerings
16.4.4. Key Developments
16.4.5. Financial Analysis
16.4.6. SWOT Analysis
16.4.7. Business Strategies
16.5. Roche Diagnostics
16.5.1. Company Details
16.5.2. Company Overview
16.5.3. Product Offerings
16.5.4. Key Developments
16.5.5. Financial Analysis
16.5.6. SWOT Analysis
16.5.7. Business Strategies
16.6. Siemens Healthcare Private Limited
16.6.1. Company Details
16.6.2. Company Overview
16.6.3. Product Offerings
16.6.4. Key Developments
16.6.5. Financial Analysis
16.6.6. SWOT Analysis
16.6.7. Business Strategies
16.7. Other Industry Participants
17. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
